Scancell

arrow choose one big pick forward many
Biotech

Scancell picks winner from phase 2 cancer vaccine face-off

Scancell linked iSCIB1+ to a 69% response rate in advanced melanoma, leading the biotech to pick the next-generation candidate over its older sibling.
Nick Paul Taylor Jul 22, 2025 9:38am
Hand reaching for juice on grocery store shelf

Genmab buys 2nd antibody from Scancell in deal worth up to $630M

Dec 4, 2024 11:55am
An artists rendering of cells in the midst of metastasis The cells are bright red with round shadows on them They appear

Scancell enjoys stock bounce on back of cancer vaccine data

Sep 19, 2023 10:55am
contract

Immunocore lifer leaves to head research at TCR rival Scancell

Jan 21, 2019 7:59am
Research

After $270M round, BioNTech pens TCR pact with Scancell

Jan 9, 2018 10:30am
Newspapers

EuroBiotech: More Articles of Note

May 11, 2017 9:19am